A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas
- Conditions
- colorectal carcinoma (CRC)
- Registration Number
- 2024-519301-36-00
- Lead Sponsor
- Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does BI 765049 target in colorectal and gastric cancers?
How does BI 765049 compare to standard-of-care therapies for advanced pancreatic and rectal cancers?
Which biomarkers are being evaluated for patient selection in the 2024-519301-36-00 Boehringer Ingelheim trial?
What are the potential adverse events associated with BI 765049 in Phase I oncology trials?
Are there combination therapies involving BI 765049 and other agents for metastatic gastroenterological cancers?